In an effort to maintain the leadership position of Enbrel in the psoriasis market amid fierce competition, Amgen has entered into a co-promotion agreement with GlaxoSmithKline under which GSK's Stiefel unit will promote the anti-tumor necrosis factor inhibitor to U.S. dermatologists.
Rep. Waxman Will support targeted document requests on white house health reform deals.
